The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease

CNS Neuroscience and Therapeutics

Volumn 17, Issue 5, 2011, Pages 411-427

  Mitchell, Robert A ^a   Herrmann, Nathan ^b   Lanctôt, Krista L ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Apathy; Dopamine; Pharmacotherapy; Stimulant

Indexed keywords

AMANTADINE; BENSERAZIDE; BROMOCRIPTINE; DEXAMPHETAMINE; DONEPEZIL; DOPAMINE; GALANTAMINE; LEVODOPA; MEMANTINE; METHYLPHENIDATE; MODAFINIL; QUETIAPINE; RIVASTIGMINE;

AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; APATHY; BEHAVIOR DISORDER; BRAIN HYPOXIA; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG MECHANISM; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; FRONTOTEMPORAL DEMENTIA; HUMAN; HYPERTENSION; INOTROPISM; LOW DRUG DOSE; MAJOR DEPRESSION; MENINGITIS; MULTIINFARCT DEMENTIA; NARCOLEPSY; NEUROIMAGING; NORMOTENSIVE HYDROCEPHALUS; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANIMALS; APATHY; BEHAVIORAL SYMPTOMS; BRAIN; CLINICAL TRIALS AS TOPIC; DOPAMINE; DOPAMINE AGENTS; HUMANS; TREATMENT OUTCOME;

EID: 80053184623     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00161.x     Document Type: Review

References (181)

1. Albert MS. Changing the trajectory of cognitive decline? N Engl J Med 2007;357:502-503.
2. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365-375.
3. Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med 2009;361:1529-1538.
4. Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: More than just cognition. An analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry 2006;77:146-148.
5. Coen RF, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331-336.
6. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, Dekosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 2002;288:1475-1483.
7. Marin RS. Apathy: Concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry 1996;1:304-314.
8. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143-162.
9. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-135.
10. Senanarong V, Poungvarin N, Jamjumras P, Sriboonroung A, Danchaivijit C, Udomphanthuruk S, Cummings JL. Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease. Int Psychogeriatr 2005;17:81-90.
11. Boyle PA, Malloy PF, Salloway S, Cahn-Weiner DA, Cohen R, Cummings JL. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:214-221.
12. Banerjee S, Murray J, Foley B, Atkins L, Schneider J, Mann A. Predictors of institutionalisation in people with dementia. J Neurol Neurosurg Psychiatry 2003;74:1315-1316.
13. Herrmann N, Lanctôt KL, Sambrook R, et al. The contribution of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 2006;21:972-976.
14. Diniz BS, Pinto JA, Jr., Gonzaga ML, Guimaraes FM, Gattaz WF, Forlenza OV. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2009;259:248-256.
15. Cummings JL, McRae T, Zhang R. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Am J Geriatr Psychiatry 2006;14:605-612.
16. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 1999;56:1388-1393.
17. Kaufer D. Beyond the cholinergic hypothesis: The effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:8-14.
18. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
19. Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: The MALT study. Int J Geriatr Psychiatry 1999;14:973-982.
20. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14:389-404.
21. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
22. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
23. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291:317-324.
24. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
25. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: A case series. Alzheimer Dis Assoc Disord 2007;21:164-166.
26. Galynker I, Ieronimo C, Miner C, Rosenblum J, Vilkas N, Rosenthal R. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997;9:231-239.
27. Koob GF. Hedonic valence, dopamine and motivation. Mol Psychiatry 1996;1:186-189.
28. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci 1996;19:319-340.
29. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 1998;80:1-27.
30. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr Scand Suppl 2005;427:14-21.
31. Lanctôt KL, Moosa S, Herrmann N, Leibovitch FS, Rothenburg L, Cotter A, Black SE. A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24:65-72.
32. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004;61:641-644.
33. Cheramy A, Leviel V, Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 1981;289:537-542.
34. Nissbrandt H, Sundstrom E, Jonsson G, Hjorth S, Carlsson A. Synthesis and release of dopamine in rat brain: Comparison between substantia nigra pars compacts, pars reticulata, and striatum. J Neurochem 1989;52:1170-1182.
35. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6:358-370.
36. Reeves S, Bench C, Howard R. Ageing and the nigrostriatal dopaminergic system. Int J Geriatr Psychiatry 2002;17:359-370.
37. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997;7:191-197.
38. Storga D, Vrecko K, Birkmayer JGD, Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Letters 1996;203:29-32.
39. Arai H, Kosaka K, Iiziku R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 1984;43:388-393.
40. Nazarali AJ, Reynolds GP. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: A postmortem study. Cellular & Molecular Neurobiol 1992;12:581-587.
41. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 1983;280:119-126.
42. Reinikainen KJ, Paljarvi L, Halonen T, Malminen O, Kosma VM, Laakso M, Riekkinen PJ. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease. Neurobiol Aging 1988;9:245-252.
43. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 1987;401:231-238.
44. Cross AJ, Crow TJ, Johnson JA, et al. Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci 1983;60:383-392.
45. Sawada M, Hirata Y, Arai H, Iizuka R, Nagatsu T. Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J Neurochem 1987;48:760-764.
46. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;37:300-312.
47. Sweet RA, Hamilton RL, Healy MT, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 2001;58:466-472.
48. Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Markakis D. Striatal dopamine receptors in Alzheimer-type dementia. Neurosci Lett 1984;52:1-6.
49. De Keyser J, Ebinger G, Vauquelin G. D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. Arch Neurol 1990;47:761-763.
50. Barbanti P, Fabbrini G, Ricci A, et al. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech Ageing Dev 2000;120:65-75.
51. Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15.
52. Kumar U, Patel SC. Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain. Brain Res 2007;1131:187-196.
53. Goldsmith SK, Joyce JN. Dopamine D2 receptors are organized in bands in normal human temporal cortex. Neuroscience 1996;74:435-451.
54. Joyce JN, Myers AJ, Gurevich E. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Res 1998;784:7-17.
55. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612.
56. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann Neurol 1995;37:300-312.
57. Joyce JN, Meador-Woodruff JH. Linking the family of D2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 1997;16:375-384.
58. Ceravolo R, Volterrani D, Gambaccini G, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: Evidence from a dopamine transporter imaging study. J Neural Transm 2004;111:1065-1073.
59. Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease. Dement Geriatr Cogn Disord 2008;26:257-260.
60. Ma SY, Ciliax BJ, Stebbins G, et al. Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra. J Comp Neurol 1999;409:25-37.
61. Pizzolato G, Chierichetti F, Fabbri M, Cagnin A, Dam M, Ferlin G, Battistin L. Reduced striatal dopamine receptors in Alzheimer's disease: Single photon emission tomography study with the D2 tracer [123I]-IBZM. Neurology 1996;47:1065-1068.
62. Videbaek C, Toska K, Scheideler MA, Paulson OB, Moos Knudsen G. SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse 2000;38:338-342.
63. Tanaka Y, Meguro K, Yamaguchi S, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease. Ann Nucl Med 2003;17:567-573.
64. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution. Brain 1999;122(Pt 8):1449-1468.
65. Piggott MA, Ballard CG, Rowan E, et al. Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. Synapse 2007;61:903-911.
66. Itoh M, Meguro K, Fujiwara T, et al. Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET. Ann Nuclear Med 1994;8:245-251.
67. Allard P, Alafuzoff I, Carlsson A, Eriksson K, Ericson E, Gottfries CG, Marcusson JO. Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease. Eur Neurol 1990;30:181-185.
68. Rinne JO, Sahlberg N, Ruottinen H, Nagren K, Lehikoinen P. Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 1998;50:152-156.
69. Slifstein M, Hwang DR, Huang Y, et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 2004;175:274-286.
70. Slifstein M, Kegeles LS, Xu X, et al. Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 2009;64:350-362.
71. Berridge KC. The debate over dopamine's role in reward: The case for incentive salience. Psychopharmacology (Berl) 2007;191:391-431.
72. Berridge KC, Robinson TE. What is the role of dopamine in reward: Hedonic impact, reward learning, or incentive salience?. Brain Res Brain Res Rev 1998;28:309-369.
73. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-723.
74. Salamone JD. The behavioral neurochemistry of motivation: Methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. J Neurosci Methods 1996;64:137-149.
75. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997;275:1593-1599.
76. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996;6:243-251.
77. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-492.
78. Benoit M, Dygai I, Migneco O, et al. Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion. Dement Geriatr Cogn Disord 1999;10:511-517.
79. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I. Cerebral blood flow correlates of apathy in Alzheimer disease. Arch Neurol 1996;53:1116-1120.
80. Migneco O, Benoit M, Koulibaly PM, et al. Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: A study in Alzheimer's disease and nondemented patients. Neuroimage 2001;13:896-902.
81. Robert PH, Darcourt G, Koulibaly MP, et al. Lack of initiative and interest in Alzheimer's disease: A single photon emission computed tomography study. Eur J Neurol 2006;13:729-735.
82. Benoit M, Clairet S, Koulibaly PM, Darcourt J, Robert PH. Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:864-869.
83. Benoit M, Koulibaly PM, Migneco O, Darcourt J, Pringuey DJ, Robert PH. Brain perfusion in Alzheimer's disease with and without apathy: A SPECT study with statistical parametric mapping analysis. Psychiatry Res 2002;114:103-111.
84. Ott BR, Noto RB, Fogel BS. Apathy and loss of insight in Alzheimer's disease: A SPECT imaging study. J Neuropsychiatry Clin Neurosci 1996;8:41-46.
85. Lopez OL, Zivkovic S, Smith G, Becker JT, Meltzer CC, DeKosky ST. Psychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2001;13:56-60.
86. Bencherif B, Stumpf MJ, Links JM, Frost JJ. Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping. J Nucl Med 2004;45:402-408.
87. Landes AM, Sperry SD, Strauss ME, Geldmacher DS. Apathy in Alzheimer's disease. J Am Geriatr Soc 2001;49:1700-1707.
88. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998;10:314-319.
89. Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990;147:22-30.
90. Marin RS, Firinciogullari S, Biedrzycki RC. The sources of convergence between measures of apathy and depression. J Affect Disord 1993;28:117-124.
91. Starkstein SE, Petracca G, Chemerinski E, Kremer J. Syndromic validity of apathy in Alzheimer's disease. Am J Psychiatry 2001;158:872-877.
92. Devinsky O, Morrell MJ, Vogt BA. Contributions of anterior cingulate cortex to behaviour. Brain 1995;118(Pt 1):279-306.
93. Blood AJ, Zatorre RJ. Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion. Proc Natl Acad Sci USA 2001;98:11818-11823.
94. Schultz W. Reward signaling by dopamine neurons. Neuroscientist 2001;7:293-302.
95. Tremblay L, Schultz W. Relative reward preference in primate orbitofrontal cortex. Nature 1999;398:704-708.
96. Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: A PET study. Neurology 2009;73:1746-1751.
97. Jonsson M, Edman A, Lind K, Rolstad S, Sjogren M, Wallin A. Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia. Int J Geriatr Psychiatry 2009. doi: .
98. Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD. Neuroimaging correlates of apathy and depression in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2009;21:259-265.
99. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007;64:1015-1020.
100. David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J, Robert P. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg 2008;110:19-24.
101. Schuff N, Zhu XP. Imaging of mild cognitive impairment and early dementia. Br J Radiol 2007;80:S109-114.
102. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis 2002;13(Suppl 2):11-15.
103. Jellinger KA. Morphologic diagnosis of "vascular dementia"- a critical update. J Neurol Sci 2008;270:1-12.
104. Jellinger KA. The pathology of "vascular dementia": A critical update. J Alzheimers Dis 2008;14:107-123.
105. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008;39:2712-2719.
106. Lopez OL, Wisnieski SR, Becker JT, Boller F, DeKosky ST. Extrapyramidal signs in patients with probable Alzheimer disease. Arch Neurol 1997;54:969-975.
107. Portet F, Scarmeas N, Cosentino S, Helzner EP, Stern Y. Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Arch Neurol 2009;66:1120-1126.
108. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997;277:806-812.
109. Merello M, Sabe L, Teson A, Migliorelli R, Petracchi M, Leiguarda R, Starkstein S. Extrapyramidalism in Alzheimer's disease: Prevalence, psychiatric, and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1994;57:1503-1509.
110. Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer's disease. Neurology 1984;34:1114-1116.
111. Gilley DW, Wilson RS, Bennett DA, Bernard BA, Fox JH. Predictors of behavioral disturbance in Alzheimer's disease. J Gerontol 1991;46:P362-371.
112. Starkstein SE, Merello M, Brockman S, Bruce D, Petracca G, Power BD. Apathy predicts more severe parkinsonism in Alzheimer's disease. Am J Geriatr Psychiatry 2009;17:291-298.
113. Joyce JN, Murray AM, Hurtig HI, Gottlieb GL, Trojanowski JQ. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease. Neuropsychopharmacology 1998;19:472-480.
114. Herrmann N, Rabheru K, Wang J, Binder C. Galantamine treatment of problematic behavior in Alzheimer disease: Post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005;13:527-534.
115. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: A subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005;20:559-569.
116. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590-1599.
117. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219.
118. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, Richardson S. Efficacy of donepezil in early-stage Alzheimer disease: A randomized placebo-controlled trial. Arch Neurol 2004;61:1852-1856.
119. Tanaka M, Namiki C, Thuy DH, et al. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J Neurol Sci 2004;225:135-141.
120. Cummings JL, Koumaras B, Chen M, Mirski D. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005;3:137-148.
121. Dartigues JF, Goulley F, Bourdeix I, Pere JJ, Barberger-Gateau P. Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease. Rev Neurol (Paris) 2002;158:807-812.
122. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004;66:538-544.
123. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: A descriptive review. Alzheimers Dement 2008;4:49-60.
124. Drayton SJ, Davies K, Steinberg M, Leroi I, Rosenblatt A, Lyketsos CG. Amantadine for executive dysfunction syndrome in patients with dementia. Psychosomatics 2004;45:205-209.
125. Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. J Neuropsychiatry Clin Neurosci 1997;9:222-230.
126. Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, Thompson W. N of 1 study: Amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj 1995;9:49-53.
127. Debette S, Kozlowski O, Steinling M, Rousseaux M. Levodopa and bromocriptine in hypoxic brain injury. J Neurol 2002;249:1678-1682.
128. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: A treatable syndrome. J Neuropsychiatry Clin Neurosci 1995;7:23-30.
129. Huey ED, Garcia C, Wassermann EM, Tierney MAM, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008;69:1981-1982.
130. Lanctôt KL, Herrmann N, Black SE, Ryan M, Rothenburg LS, Liu BA, Busto UE. Apathy associated with Alzheimer disease: Use of dextroamphetamine challenge. Am J Geriatr Psychiatry 2008;16:551-557.
131. Chatterjee A, Fahn S. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:461-462.
132. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL. Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 2008;28:296-301.
133. Keenan S, Mavaddat N, Iddon J, Pickard JD, Sahakian BJ. Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: A case study and review. Br J Neurosurg 2005;19:46-50.
134. Maletta GJ, Winegarden T. Reversal of anorexia by methylphenidate in apathetic, severely demented nursing home patients. Am J Geriat Psychiat 1993;1:234-243.
135. Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independent of depression. Ann Pharmacother 2005;39:1947-1949.
136. Padala PR, Burke WJ, Bhatia SC, Petty F. Treatment of apathy with methylphenidate. J Neuropsychiatry Clin Neurosci 2007;19:81-83.
137. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010;18:371-374.
138. Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008;69:87-94.
139. Spiegel DR, Kim J, Greene K, Conner C, Zamfir D. Apathy due to cerebrovascular accidents successfully treated with methylphenidate: A case series. J Neuropsychiatry Clin Neurosci 2009;21:216-219.
140. Padala PR, Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 2007;41:346-349.
141. Challman TD, Lipsky JJ. Methylphenidate: Its pharmacology and uses. Mayo Clin Proc 2000;75:711-721.
142. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1410-1415.
143. Herrmann N, Lanctôt KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 2004;16:261-276.
144. Unis AS, Dawson TM, Gehlert DR, Wamsley JK. Autoradiographic localization of [3H]methylphenidate binding sites in rat brain. Eur J Pharmacol 1985;113:155-157.
145. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999;340:780-788.
146. Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH. Toward individualized evidence-based medicine: Five "N of 1" trials of methylphenidate in geriatric patients. J Am Geriatr Soc 2001;49:474-476.
147. Kuczenski R, Segal DS, Cho AK, Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 1995;15:1308-1317.
148. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG. Multiple ionic conductances of the human dopamine transporter: The actions of dopamine and psychostimulants. J Neurosci 1997;17:960-974.
149. Clemens JA, Fuller RW. Differences in the effects of amphetamine and methylphenidate on brain dopamine turnover and serum prolactin concentration in reserpine-treated rats. Life Sci 1979;24:2077-2081.
150. Endres CJ, Kolachana BS, Saunders RC, et al. Kinetic modeling of [11C]raclopride: Combined PET-microdialysis studies. J Cereb Blood Flow Metab 1997;17:932-942.
151. Laruelle M, Iyer RN, al-Tikriti MS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997;25:1-14.
152. Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001;49:81-96.
153. Volkow ND, Wang GJ, Fowler JS, et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999;291:409-415.
154. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:5274-5278.
155. Sharp T, Zetterstrom T, Ljungberg T, Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res 1987;401:322-330.
156. de Wit H, Enggasser JL, Richards JB. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 2002;27:813-825.
157. Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer EA. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 1995;47:368-373.
158. Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: Effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993;33:639-677.
159. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 2000;20:3504-3511.
160. Hill HE, Haertzen CA, Wolbach AB, Jr., Miner EJ. The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine. Psychopharmacologia 1963;4:167-183.
161. Laruelle M, Abi-Dargham A, van Dyck CH, et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995;36:1182-1190.
162. Cardenas L, Houle S, Kapur S, Busto UE. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 2004;51:27-31.
163. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: Altered response to dextroamphetamine. Arch Gen Psychiatry 2002;59:409-416.
164. Tremblay LK, Naranjo CA, Graham SJ, Herrmann N, Mayberg HS, Hevenor S, Busto UE. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005;62:1228-1236.
165. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005;58:779-786.
166. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60.
167. Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002;13:105-115.
168. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: An antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997;42:1181-1183.
169. Mignot E, Nishino S, Guilleminault C, Dement WC. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994;17:436-437.
170. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794.
171. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, Saper CB. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628.
172. Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med 2000;1:109-116.
173. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451.
174. Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, Lubin S. Modafinil: A double-blind multicentric study. Sleep 1994;17:S107-112.
175. Baranski JV, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004;19:323-332.
176. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003;165:260-269.
177. Lyons TJ, French J. Modafinil: The unique properties of a new stimulant. Aviat Space Environ Med 1991;62:432-435.
178. Pigeau R, Naitoh P, Buguet A, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995;4:212-228.
179. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988;14:35-51.
180. Boyd A. Bromocriptine and psychosis: A literature review. Psychiatr Q 1995;66:87-95.
181. Roccaforte WH, Burke WJ. Use of psychostimulants for the elderly. Hosp Community Psychiatry 1990;41:1330-1333.